Moleculin Reveals Final Topline Data From European Study Of Annamycin In Leukemia Setting

Moleculin Biotech Inc MBRX announced the topline results from its MB-105 European Phase 1 clinical trial assessing the safety and efficacy of Annamycin as a single agent for relapsed or refractory acute myeloid leukemia (AML).
The final MB-105 results align with the overall safety profile of Annamycin and observations made in previously completed and ongoing clinical studies evaluating Annamycin.
Additionally, in the last cohort, where all subjects were at least 60 years of age, Annamycin demonstrated an overall response rate (ORR) of 80%.
Related: Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response Rate.
"We also are encouraged by the absence of cardiotoxicity with Annamycin to date," said Chairman and CEO Walter Klemp.
"This is particularly relevant in light of a recently published retrospective study showing that the incidence of heart failure more than doubles for cancer patients treated with anthracyclines compared to cancer patients not receiving anthracyclines," Klemp added.
Topline results showed one CRi (complete response with incomplete recovery of peripheral blood count) and three PRs (Partial Response) for an 80% overall response rate (ORR) in the last cohort of elderly patients.
Price Action: MBRX shares are up 0.44% at $1.18 on the last check Monday